ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

March 12, 2008 09:15 ET

ALDA Files 2006 20F With SEC

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 12, 2008) - ALDA Pharmaceuticals Corp. ("ALDA") (TSX VENTURE:APH) has completed the filing of its June 30, 2006 20F registration statement on the SEC's EDGAR system. The next step, after receiving comments from the SEC reviewer, will be to file the June 30, 2007 registration statement.

Dr. Terrance Owen, President & CEO, states, "We are catching up on our filings with the SEC after a long hiatus while we contemplated our foreign listing strategy. Management has decided that it is advantageous to continue with the US registration of ALDA's securities and we plan to move forward as quickly as possible. We also feel this is an appropriate time to present the company to a broader audience. Accordingly, we will be meeting with selected representatives of the investment community in Calgary, Edmonton, Toronto, Ottawa and Montreal in the next few weeks to discuss ALDA's progress."

About ALDA Pharmaceuticals

ALDA is focused on the development of infection control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp. - Distribution & Sales Contact
    Peter Chen
    CFO and Director
    (604) 521-8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp. - Investor Relations Contact
    Scott Young
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com